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Although stroke is the third leading cause of death in the United States, rela-
tively little is known about the disease. Philip A. Wolf, M.D., heads a BUSM 
research team that is exploring the causes of stroke and the best methods 
for treatment. See story on page 3. 
These before and after pictures iiiustrate the dramatic improvement brought about by the use of 
isotretinoin (13-cis-retinoic acid) in the treatment of severe acne. (Department of Dermatology 
photos) 
Physician aims to improve diagnosis 
of MS: 'crippier of young aduits' 
Major breakthrough 
occurs in acne 
treatment with 
drug development 
A major breakthrough in the man-
^ ^ g e m e n t of severe, treatment-
3sistant acne, based in part on 
research at Boston University Medi-
cal Center, has been approved by 
the federal Food and Drug 
Administration. 
Acne is a common skin disease 
affecting more than 15 million ado-
lescents in the United States 
between the ages of 12 and 17, in 
addition to adults in their 20s, 30s, 
and even 40s. Severe cases only 
number about 350,000, but represent 
an important subset of patients 
because of morbidity and resistance 
of their disease to treatment. 
Since 1979, Peter E. Pochi, M.D., a 
BUSM professor of dermatology, 
and his team of researchers in the 
Evans Memorial Department of Clin-
ical Research at University Hospital 
in Boston, a principal teaching hos-
pital of BUSM, have been studying 
the efficacy and safety of an orally 
administered vitamin A derivative, 
isotretinoin (13-cis-retinoic acid) in 
cases of severe, treatment-resistant 
acne. The drug had been tested first 
^ t the National Cancer Institute and 
lowed dramatically beneficial 
results in a small group of patients. 
Although the exact mechanism of 
the action of this compound has not 
been determined yet, Pochi said cl in-
continued on page 2 
By the time 25-year-old Kate sought 
the advice of her family physician, 
the numbness in her left leg was 
persistent and her vision frequently 
was blurred. At times, she stumbled 
for no apparent reason and seemed 
to tire easily. For weeks, she had told 
herself that these vague symptoms, 
some of which would come and go, 
simply meant that she was over-
worked or "under the weather." 
The final diagnosis of Kate's 
symptoms was multiple sclerosis, a 
major disorder of the central nervous 
system that now affects an estimated 
250,000 persons in the United States, 
according to Charles M. Poser, M.D., 
a professor of neurology at Boston 
University School of Medicine and a 
nationally-recognized authority in 
the field of MS. 
Often referred to as the "crippler 
of young adults," multiple sclerosis 
usually strikes those in the 20-to-40 
age bracket, affecting women more 
continued on page 5 
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Acne breakthrough... 
continued from page 1 
ical trials, funded by Hoffmann-La 
Roche, Inc., the drug's developer, 
have shown that the drug is highly 
effective, even in severe cases resis-
tant to most other treatments. The 
drug will be on the market in 
September. 
Of the 65 patients Pochi has 
treated, not a single case of facial 
acne failed to clear up completely in 
patients administered adequate 
doses for an appropriate length of 
time. Cases of back and chest acne 
usually responded well, although not 
always as completely as facial acne. 
Side effects were limited primarily to 
the skin and the mucous membranes, 
he said. 
Acne consists of both inflamma-
tory and non-inflammatory lesions. 
The non-inflammatory l es i ons -
blackheads and whiteheads—are 
caused by retention of dead skin 
cells and hardened oils lodged 
deeply in the follicles (pores) of the 
skin in such acne-susceptible areas 
of the skin as the face, neck, chest 
and back. The inflammatory compo-
nent is comprised of papules (red 
pimples), pustules (pus-pimples) 
and large inflammatory nodules 
("cysts"). When these large inflam-
matory lesions are numerous, the 
term cystic or conglobate acne is 
used. This type of acne tends to be 
resistant to treatment and to lead to 
the formation of scars, Pochi said. 
Initially, it was believed that isotre-
tinoin was effective in acne by reduc-
ing the formation of sebum, the oil 
gland secretion. Pochi's former 
associate investigators, John S. 
Strauss, M.D., and Donald T. Down-
ing, Ph.D., who now are at the Uni-
versity of Iowa College of Medicine, 
conducted at University Hospital the 
first tests measuring the composition 
of sebum in patients already being 
treated with the drug. In these tests 
it was discovered that patients on 
the drug had very low levels of 
sebum oils. "It was an indirect mea-
sure, but we were convinced that 
was what the drug was doing. Sub-
sequently, we were able to do oil 
measurements directly on patients 
with severe acne before and after 
treatment. The drug decreased oil 
secretion by nearly 90 percent," 
Pochi said. 
Shortly afterwards, the research-
ers conducted a head-on test in 
which isotretinoin was compared 
with etretinate, another oral vitamin 
A-derivative drug that had been 
tested in Europe for the treatment of 
psoriasis, to see which one worked 
better in severe acne cases. 
"It was no contest," Pochi said. "It 
was very interesting because the 
drugs were so similar—the same 
type of compound. They both 
belonged to a group of substances 
called retinoids, which are vitamin A 
derivatives. But one worked and one 
didn't. That's characteristic of reti-
noids. They can affect a variety of 
diseases differently. The other drug 
didn't even reduce oil secretion. It 
was a double-blind study, but it was 
not difficult to tell after several 
weeks who was on which drug." In a 
continuation of this study, Pochi 
said, those given etretinate were 
afforded the opportunity to be 
treated with isotretinoin, and most 
did very well. 
Isotretinoin has a very high 
response rate despite the severity of 
the disease, Pochi said, citing a 
dose-response study now nearing 
completion on the efficacy and the 
incidence and severity of the drug's 
side effects. The BUMC research 
team undertook the study in collabo-
ration with departments of derma-
tology at State University of New 
York, Downstate Medical Center, 
Brooklyn, and University of Iowa 
College of Medicine, Iowa City. 
Since last summer, 150 patients 
with severe acne have been treated 
at the three institutions with three 
different dosages of isotretinoin for 
16 to 20 weeks. In this blind study, 
yet to be analyzed, only the patient 
and the technician administering the 
drug, not the physicians, knew 
which patient was receiving what 
dosage. If after 16 weeks there was 
not a 75 percent decrease in the 
number of nodulocystic lesions, the 
patient would continue treatment for 
four more weeks. Patients then were 
followed for two months after the 
drug was stopped. 
"What we noticed as had others 
previously, and what is still unex-
plained, is that patients continue to 
improve after the drug is stopped. 
You don't get your ultimate benefit 
until approximately two months after 
the drug is stopped," Pochi said. 
Although this implies that the drug 
stays in the body, that apparently is 
not the case. The drug is actually 
eliminated fairly rapidly. "Fifty per-
cent of the drug is eliminated from 
the body after 10 to 20 hours," he 
explained. 
Several other questions remain to 
be answered about the drug. 
"What's puzzling is that the oil 
glands recover after the drug is 
stopped, yet the disease, if it has 
responded well, rarely comes back," 
Pochi said. When there are recur-
rences, they are relatively minor. The 
drug shuts off the oil glands imme-
diately. Oil secretion goes down 
abruptly, then comes back very 
slowly. But it always comes back. 
However, when it does, the patient's 
disease usually is still quiescent. 
There were two patients who did 
not respond to treatment at all de-
spite very marked inhibition of 
sebaceous gland secretion. "The 
results in these two patients suggest 
that the reduction of sebum, induced 
by isotretinoin administration, may 
not represent the only way the drug 
acts in alleviating the severity of 
acne," Pochi said. 
Another factor in the disease 
besides oil secretion is acne bacte-^-
ria, known as Propionibacterium 
acnes. Everyone has these bacteria, 
which reside deeply in acne-
susceptible follicles. People who 
have acne get in trouble because 
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School of Medicine research team 
seeks to unravel mysteries of stroke 
their pore walls develop abnormally 
and are prone to break down. The 
bacteria produce many enzymes and 
acids so when the walls break, 
inflammation is the result. Recent 
research has shown that with use of 
isotretinoin, these bacteria decrease 
markedly. "Yet the drug is not anti-
bacterial perse," Pochi said. The 
bacteria probably decrease because 
one of the functions of sebum is to 
provide food for the bacteria. It is 
not yet known whether the bacteria 
recover, as does sebum, when the 
drug is stopped. 
Now in the final stages of his cl ini-
cal investigation on isotretinoin, 
Pochi has turned his attention to 
possible endocrine abnormalities in 
adult women with persistent acne. 
^ Acne in women over age 20 can 
e a sign of an overactive ovary or 
adrenal gland, but in these cases, it 
almost always occurs along with 
excessive facial hair and menstrual 
irregularities. 
"Most women with acne do not 
have other symptoms and hormon-
ally seem to be normal," Pochi said. 
"Yet, in many cases, the acne per-
sists and frequently resists 
treatment'.' 
To examine this problem, Pochi is 
conducting a three-year National 
Institutes of Health-supported study 
in collaboration with Christopher 
Longcope, M.D., a professor of 
obstetrics/gynecology and medicine 
at University of Massachusetts Med-
ical School. 
—Shirley B. Moskow 
Suggested Further Readings 
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gland inhibition from combined 
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3. Farrell, L.N. et al: The treatment of severe 
cystic acne with 13-cis-retinoic acid. Eval-
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Behind the popular perception of 
stroke as a disease that hits sud-
denly, and often leaves victims para-
lyzed or unable to speak, lie some 
little-known facts about the illness: 
• While stroke is a member of the 
family of diseases that includes 
heart attacks, some factors that 
significantly increase the risk of 
heart attacks—notably smoking 
and high cholesterol—seem to 
have little connection with 
stroke. 
• The kind of problem that brings 
on a stroke has a lot to do with 
how serious and long-lasting its 
effects will be. Strokes that result 
from hemorrhage, for example, 
are far more likely to lead to 
death, or permanent disability, 
than those resulting from blood 
clots or a narrowing of the arter-
ies, which make up about 80 
percent of the total number of 
strokes. 
• Although stroke can in fact para-
lyze victims, or seriously affect 
them in other ways, it may occa-
sionally produce little or no 
permanent damage. 
Even though stroke is the nation's 
third leading cause of death, with 
500,000 victims yearly, stroke is still, 
relatively speaking, a mystery. Des-
pite the emergence of new findings 
over recent decades, much less is 
known about stroke than about 
other major diseases. 
Currently involved in a multifa-
ceted effort to shed added light on 
the causes of stroke and the best 
methods for treating it is a Boston 
University School of Medicine team 
headed by Philip A. Wolf, M.D., a 
professor of neurology and an asso-
ciate research professor of medicine. 
Part of the group's effort is cen-
tered on BUSM's renowned Fra-
mingham Heart Study, in which 
health patterns of more than 5,000 
men and women have been tracked 
for more than 30 years. 
The Study, named for the com-
munity of Framingham, Mass., where 
all its subjects lived at the time the 
project began, is best known for its 
contributions to the understanding 
of heart disease. It also has helped 
advance understanding of stroke. 
Thus, noted Wolf, more than a 
decade ago an examination of stroke 
incidence in the Framingham group 
confirmed a strong link between 
hypertension and stroke. More 
recently, BUSM researchers used 
the Framingham group to show that 
doctors frequently fail to report 
accurately on whether stroke was a 
cause of death. 
Now, Wolf and his associates have 
embarked on a new examination of 
stoke patterns in the Framingham 
group, with support from the 
National Institute for Neurological 
and Communicative Disorders and 
Stroke. Working with Wolf in this and 
other stroke studies are Lee Corwin, 
M.D., a staff neurologist at University 
Hospital in Boston, a principal teach-
ing hospital of BUSM, Margaret 
Kelly-Hayes, R.N., M.S., an assistant 
clinical professor of neurology, 
Eloise Licata-Gehr, R.N., M.S., a 
stroke research nurse, and Paula J. 
Murray, data manager. 
One of the major issues being 
examined, said Wolf, is the role of 
noises, known technically as carotid 
bruits, which sometimes can be 
identified as coming from arteries 
leading to the brain, as a potential 
warning sign for stroke. 
"These bruits may be testimony to 
the existence of atherosclerosis, or a 
narrowing of the arteries," said the 
neurologist. "On the other hand, 
there's a lot of controversy about the 
extent of the risk facing people with 
bruits, and about whether you ought 
to do extensive tests on them, which 
are potentially dangerous, or to 
operate." 
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Neurologist Philip A. Wolf, l\/I.D., examines a patient in his University Hospital office. (Photo by 
Bradford F. Herzog) 
If it is found that certain people 
with bruits are at no greater risk of 
stroke, then hazardous tests and 
surgery would not be justified. Wolf 
said. Digital subtraction angiography 
(DSA), a new technique that permits 
visualization of the carotid and cere-
bral arteries without the risks of arte-
riography, also can be used. 
A second area of investigation is 
the link between stroke and dia-
betes. Many studies have shown that 
individuals with diabetes are more 
subject to stroke than their non-
diabetic counterparts, Wolf noted. 
Yet, the question remains whether 
this is simply because diabetes and 
stroke are both linked to the same 
risk factors—especially hypertension 
—or because diabetes has an impact 
on the system that itself increases 
the risk of stroke. 
"The brain makes use of glucose, 
and diabetes obviously interferes 
with glucose metabolism," Wolf said. 
"What we may be seeing, therefore, 
is diabetes acting to make the brain 
more vulnerable to cerebrovascular 
attacks." 
A third subject under scrutiny is 
the question of why stroke, on the 
average, tends to occur so much 
later in life than heart attacks. While 
stroke is rare among those under 60, 
heart attacks frequently strike peo-
ple, especially men, in their 40s and 
50s. 
"We really have very little idea 
what accounts for the age differ-
ence," Wolf said. "It could have 
something to do with the way hyper-
tension seems to act in producing 
atherosclerosis—driving the buildup 
of plaque in the arteries out further 
and further from the heart, so that 
eventually it affects the arteries lead-
ing to the brain." 
Insight into this question could 
provide information about the condi-
tions that lead to stroke, said the 
neurologist. This, in turn—like f ind-
ings on the role of bruits, diabetes 
and other potential precursors of 
stroke—could lead to improved 
strategies for preventing the disease. 
In addition to seeking knowledge 
that will be useful in prevention, the 
BUSM group also is hoping to aid in 
improving treatment strategies. Both 
in the Framingham project and in 
the Full Phase Stroke Data Bank proj-
ect at University Hospital, they are 
looking for answers to such ques-
tions as: 
• What kinds of home-care are 
required for people who have been 
seriously disabled by stroke? 
• How can the medical communi-
ty's identification of different kinds 
of stroke be improved and 
standardized? 
• And—an issue that is especially 
critical at a time of growing con-
straints on health-care spending— 
can better predictions be made, 
based on the type of stroke and the 
brain area affected, about the need 
for therapy and its chances for 
success? 
"Since resources are limited," 
Wolf said, "it would be tremendously 
valuable to be able to predict which 
patients are going to do very well, 
which ones are unlikely to respond 
to even the most intensive treatment, 
and which ones can, through ther-
apy, be brought to a level of inde-
pendence that would enable them to 
live fairly normal lives." 
—Richard P. Anthony 
Suggested Further Readings 
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Multiple sclerosis... 
continued from page 1 
frequently than men. A progressive, 
unpredictable disease with no 
known cause or cure, MS is more 
prevalent in colder climates-
But one of the biggest problems 
with MS is the diagnosis. 
"There is no single diagnostic 
laboratory test specific to MS," 
Poser stated. "The diagnosis is 
based on clinical information the 
physician gleans from the patient's 
history and from a neurological 
examination, using criteria devel-
oped 15 or 20 years ago—before 
such procedures as evoked 
response studies or CAT-scans were 
^ introduced," he continued. (Evoked 
response studies use such external 
stimuli as visual patterns or clicking 
sounds to measure the brain's elec-
trical response.) 
To further complicate the problem 
of diagnosing multiple sclerosis, an 
average of 3.3 years may pass after a 
patient has the first symptom before 
he or she is diagnosed. Poser 
explained. "That's because the 
symptoms often are disregarded by 
the patient or misinterpreted by the 
doctor." 
I As evidence of the lack of stan-
dardization in diagnosing multiple 
sclerosis. Poser in 1965 conducted a 
, test that demonstrated a remarkable 
absence of correlation among diag-
nostic criteria. He collected detailed 
^ clinical histories of 25 patients who 
I had died and whose autopsies con-
j firmed previous MS diagnoses. 
I Poser sent these reports to 106 neu-
rologists around the world who clas-
sified each case as probable, possi-
I ble or unlikely MS, using any criteria 
they wished. 
The results were astounding: 40 
percent of the cases were rated 
-(^ "unlikely." In other words, if Kate, 
mentioned earlier in this article, con-
sulted those same 106 neurologists, 
complained of the same symptoms 
and provided the same clinical his-
Charles M. Poser, M.D., conducts a diagnostic test for multipie sclerosis. (Photo by Bradford F. 
Herzog) 
tory, 42 of the 106 would tell her that 
it was unlikely she was suffering 
from MS. 
"We have been making diagnoses 
based on tests of variable reliability," 
Poser said. "These criteria must be 
standardized because they are being 
increasingly depended upon by a 
growing number of neurologists. In 
addition," he continued, "it is vital to 
have a single, agreed-upon set of 
criteria to conduct valid epidemio-
logical studies of the disease or to 
engage in clinical trials of drug reg-
imens for the treatment of MS." 
To help standardize the process of 
diagnosing MS, Poser has developed 
a numerical system that is based 
upon the scoring of historical, exam-
ination and ancillary clinical diag-
nostic procedures. Poser believes 
that the utilization of this simple 
numerical scale will help standardize 
the three traditional classifications of 
MS: possible, probable and definite. 
(If the cases Poser used in 1965 
were evaluated using the scoring 
system, the accuracy of diagnosis 
would be increased to between 80 
and 85 percent rated "definite," he 
noted.) 
"The application of the scoring 
system still requires the initial suspi-
cion of MS on the part of the physi-
cian for it to be utilized as a diagnos-
tic tool," Poser emphasized. 
For each parameter included in 
Poser's criteria, such as age of onset 
and first symptoms experienced, a 
numerical value is assigned. That 
number corresponds to the percen-
tage of that item's occurrence 
among 111 autopsy-proven former 
MS patients from the United States, 
England and Norway. The scoring 
system is cumulative: Once a symp-
tom has occurred, its value remains 
even though it is not present at the 
time of examination. 
Appropriate scoring values also 
are awarded when such procedures 
as evoked response studies and 
psychological testing provide evi-
dence of central nervous system 
lesions, or areas where there is loss 
of tissue or function. 
To update clinical diagnostic cr i -
teria for MS, a two-day workshop 
was convened this spring in 
Washington, D.C. One major pur-
pose of the meeting, of which Poser 
was program chairman, was to 
review in detail newly-developed 
diagnostic techniques for MS. These 
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include neurophysiological tests 
such as evoked response studies, 
neuropsychological tests, neuro-
radiological procedures (CAT-scans 
and nuclear magnetic resonance 
scans), as well as immunological 
and urogical tests. 
The 25 physicians attending the 
conference, which was sponsored 
by the Paralyzed Veterans of Amer-
ica, were among the leading authori-
ties on MS from the United States, 
Canada and Great Britain. The par-
ticipants, including Daniel Sax, M.D., 
a professor of neurology at BUSM, 
assessed whether a series of diag-
nostic scenarios could be designed 
that would lead to a diagnosis of MS, 
or remove it from consideration, in a 
rapid, efficient and economical 
fashion. 
Workshop participants also estab-
lished standards for the performance 
of laboratory tests and the interpre-
tation of test results. "If a neurologist 
wants to use evoked response tests 
in the diagnosis of MS, then it 
should be done according to a cer-
tain method," Poser said. "That way, 
the results can be clearly judged as 
normal or abnormal. The physician's 
subjectivity can no longer bias this 
determination." 
In addition. Poser said, a new sys-
tem for the diagnostic classification 
of MS is being developed that will 
permit the use of these laboratory 
procedures, but only if they conform 
to the standardized methods decided 
upon at the workshop. The numeri-
cal scoring system, he added, can be 
used in conjunction with or as an 
alternative to the diagnostic classifi-
cation of MS. The diagnostic criteria 
and other recommendations result-
ing from the workshop are sched-
uled to be published next April by 
Thieme-Stratton in New York. 
The final diagnosis for multiple 
sclerosis is based upon evidence of 
two or more separate lesions of the 
central nervous system. Just as elec-
trical wires are insulated, nerve f i -
bers of the central nervous system 
are insulated with a fatty covering 
known as myelin. If the myelin 
sheath is destroyed, conduction of 
sensory or motor nerve impulses to 
the brain are impaired or may be 
completely blocked. When the brain 
no longer receives information from 
the environment or when it cannot 
direct the muscles and other organs 
to perform various functions quickly 
and smoothly, symptoms of neuro-
logical dysfunction appear, and the 
patient complains of being unable to 
function normally. 
In MS patients, lesions are gener-
ally located in five specific areas of 
the central nervous system: the spi-
nal cord, brainstem, cerebellum, 
optic nerve and the cerebral hemi-
spheres. The clinical symptoms of 
the disease may vary greatly, 
depending on the site of the lesion. 
For example, spinal cord lesions can 
produce numbness, lessened or 
absent sensitivity to pain, and lack of 
position sense (the awareness of the 
relationship of one's body parts to 
space), while lesions in the brain-
stem can cause double vision, invol-
untary movements of the eyeball or 
slurred speech. Many lesions, in par-
ticular those affecting the cerebral 
hemispheres, produce no recogniz-
able symptoms. '^"H 
Once a diagnosis of MS has been 
established, patients like Kate can 
begin a treatment plan. Although no 
single therapy is universally pre-
scribed, such medications as cort i-
costeroids and muscle relaxants 
often are used and may help the 
patient manage his or her condition. 
Other substances such as Interferon 
are being studied for their use in 
treating MS. 
In addition to the Paralyzed Veter-
ans of America, Poser's work is 
funded by the National Multiple 
Sclerosis Society and the Kroc 
Foundation. 
—Susan B. Rabin 
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